Reliant Technologies Announces FDA Clearance Of The Fraxel(R) Laser For The Treatment Of Acne And Surgical Scars

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--March 27, 2006--Reliant Technologies today announced that it has received U.S. Food and Drug Administration (FDA) clearance to market a new indication for its breakthrough Fraxel(R) Laser that enables physicians to treat acne scars and surgical scars. Until now, facial scarring has been difficult to treat with even the most aggressive topical and abrasive therapies. This has been a major disappointment to adult patients who must carry the stigma of adolescent acne long after their skin is free of active acne, or to those individuals who are left with a permanent reminder of a past surgery.

Back to news